Wells Fargo’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.58M | Sell |
713,625
-7,223
| -1% | -$12.9K | ﹤0.01% | 3442 |
|
|
2025
Q4 | $1.17M | Sell |
720,848
-9,868
| -1% | -$15.2K | ﹤0.01% | 3841 |
|
|
2025
Q3 | $950K | Sell |
730,716
-32,398
| -4% | -$28.1K | ﹤0.01% | 3857 |
|
|
2025
Q2 | $252K | Sell |
763,114
-23,433
| -3% | -$7.06K | ﹤0.01% | 4635 |
|
|
2025
Q1 | $245K | Buy |
786,547
+42,740
| +6% | +$26.3K | ﹤0.01% | 4554 |
|
|
2024
Q4 | $694K | Buy |
743,807
+8,622
| +1% | +$9.65K | ﹤0.01% | 3960 |
|
|
2024
Q3 | $868K | Sell |
735,185
-6,455
| -0.9% | -$6.74K | ﹤0.01% | 3640 |
|
|
2024
Q2 | $570K | Buy |
741,640
+307,768
| +71% | +$856K | ﹤0.01% | 3829 |
|
|
2024
Q1 | $1.32M | Sell |
433,872
-14,719
| -3% | -$49.3K | ﹤0.01% | 3267 |
|
|
2023
Q4 | $1.44M | Buy |
448,591
+3,625
| +0.8% | +$12.4K | ﹤0.01% | 3159 |
|
|
2023
Q3 | $1.71M | Sell |
444,966
-6,001
| -1% | -$21.6K | ﹤0.01% | 2923 |
|
|
2023
Q2 | $1.48M | Buy |
450,967
+20,306
| +5% | +$69K | ﹤0.01% | 3149 |
|
|
2023
Q1 | $1.11M | Buy |
430,661
+1,505
| +0.4% | +$3.57K | ﹤0.01% | 3300 |
|
|
2022
Q4 | $798K | Sell |
429,156
-5,664
| -1% | -$9.65K | ﹤0.01% | 3371 |
|
|
2022
Q3 | $800K | Buy |
434,820
+2,819
| +0.7% | +$5.9K | ﹤0.01% | 3384 |
|
|
2022
Q2 | $929K | Sell |
432,001
-2,852
| -0.7% | -$6.89K | ﹤0.01% | 3333 |
|
|
2022
Q1 | $1.36M | Sell |
434,853
-17,514
| -4% | -$55.1K | ﹤0.01% | 3628 |
|
|
2021
Q4 | $1.45M | Sell |
452,367
-1,750
| -0.4% | -$6K | ﹤0.01% | 3804 |
|
|
2021
Q3 | $1.53M | Buy |
454,117
+500
| +0.1% | +$1.82K | ﹤0.01% | 3898 |
|
|
2021
Q2 | $1.77M | Sell |
453,617
-4,668
| -1% | -$18.4K | ﹤0.01% | 3789 |
|
|
2021
Q1 | $1.84M | Sell |
458,285
-93,474
| -17% | -$310K | ﹤0.01% | 3767 |
|
|
2020
Q4 | $1.27M | Buy |
551,759
+16,673
| +3% | +$77.7K | ﹤0.01% | 3841 |
|
|
2020
Q3 | $3.07M | Buy |
535,086
+14,651
| +3% | +$98K | ﹤0.01% | 2969 |
|
|
2020
Q2 | $3.84M | Buy |
520,435
+30,614
| +6% | +$143K | ﹤0.01% | 2733 |
|
|
2020
Q1 | $1.46M | Buy |
489,821
+16,188
| +3% | +$54.5K | ﹤0.01% | 3261 |
|
|
2019
Q4 | $1.97M | Buy |
473,633
+51,933
| +12% | +$164K | ﹤0.01% | 3359 |
|
|
2019
Q3 | $1.37M | Sell |
421,700
-20,904
| -5% | -$47.5K | ﹤0.01% | 3623 |
|
|
2019
Q2 | $819K | Buy |
442,604
+128,618
| +41% | +$230K | ﹤0.01% | 4029 |
|
|
2019
Q1 | $556K | Buy |
313,986
+307,087
| +4,451% | +$768K | ﹤0.01% | 4271 |
|
|
2018
Q4 | $17K | Sell |
6,899
-48
| -0.7% | -$219 | ﹤0.01% | 5817 |
|
|
2018
Q3 | $39K | Buy |
6,947
+433
| +7% | +$3.28K | ﹤0.01% | 5669 |
|
|
2018
Q2 | $51K | Sell |
6,514
-324
| -5% | -$2.78K | ﹤0.01% | 5587 |
|
|
2018
Q1 | $48K | Buy |
6,838
+6,053
| +771% | +$49K | ﹤0.01% | 5574 |
|
|
2017
Q4 | $8K | Buy |
785
+433
| +123% | +$3.98K | ﹤0.01% | 5972 |
|
|
2017
Q3 | $3K | Buy |
+352
| New | +$2.93K | ﹤0.01% | 6110 |
|
Other funds holding OVID
RCM
AAA
EAM
VCM
ACM
SVCM
Wells Fargo's OVID Position: Q1 2026 in Review
Wells Fargo reduced its Ovid Therapeutics (OVID) stake by 1% in Q1 2026, selling an estimated $12.9K and leaving 713,625 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3442.
Wells Fargo first reported a position in OVID in Q3 2017 and has held it in 35 quarters since. The position peaked at $3.84M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.
- Wells Fargo held 713,625 shares of Ovid Therapeutics worth $1.58M as of Q1 2026.
- Wells Fargo sold 7,223 Ovid Therapeutics shares in Q1 2026, an estimated $12.9K.
- Ovid Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3442 holding.
- Wells Fargo first reported a position in Ovid Therapeutics in Q3 2017 and has held it in 35 quarters since.
- Wells Fargo's Ovid Therapeutics position peaked at $3.84M in Q2 2020.
- 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.